Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 9/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20080888 | 0.86 | NOTUM (0.58) | HSD17B10MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL3243736 | 0.79 | NOTUM (0.53) | HSD17B10MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL8320138 | 0.79 | SIRT6 (0.59) | HSD17B10MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL8320134 | 0.79 | NOTUM (0.52) | HSD17B10MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL13801246 | 0.78 | NOTUM (0.52) | HSD17B10MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL3805648 | 0.77 | NOTUM (0.61) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL255333 | 0.76 | ADRB1 (0.65) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5296091 | 0.76 | KMT2A (0.52) | HSD17B10MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL2921346 | 0.75 | DPP4 (0.51) | HSD17B10MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL6240445 | 0.75 | NOTUM (0.49) | HSD17B10MEN1KMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1997370-A | Medicaments containing N-sulfamoyl-N' -arylpiperazines for the prophylaxis or treatment of obesity and related diseases | SOLVAY PHARM GMBH (DE) | 2007-07-11 | — | — | CN | claimed |
| EP-1750712-A2 | MEDICAMENTS CONTAINING N-SULFAMOYL-N'-ARYLPIPERAZINES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | Solvay Pharmaceuticals GmbH (DE) | 2007-02-14 | — | — | EP | claimed |
| WO-2005110413-A2 | MEDICAMENTS CONTAINING N-SULFAMOYL-N'-ARYLPIPERAZINES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-11-24 | — | — | WO | claimed |
| US-20050261292-A1 | Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-11-24 | — | — | US | claimed |
| CN-1997370-B | Use of N-sulfamoyl-N' -arylpiperazines for the production of medicaments for the prophylaxis or treatment of obesity and related diseases | SOLVAY PHARM BV | 2011-06-01 | — | — | CN | disclosed |
| EP-1951725-B1 | N-SULFAMOYL-N -BENZOPYRANPIPERIDINES AS INHBITORS OF CARBONIC ANHYDRASES | ABBOTT PRODUCTS GMBH (DE) | 2010-11-03 | — | — | EP | disclosed |
| US-7772225-B2 | N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-7547708-B2 | N-sulfamoyl-N′-benzopyranpiperidine compounds and uses thereof | SOLVAY PHARMACEUTICALS, INC. (DE) | 2009-06-16 | — | — | US | disclosed |
| CN-101326166-A | Novel N-sulfamoyl-piperidine amides for the prevention or treatment of obesity and related disorders | SOLVAY PHARM GMBH (DE) | 2008-12-17 | — | — | CN | disclosed |
| CN-101309923-A | N-sulfamoyl-N' -benzopyran piperidines as carbonic anhydrase inhibitors | SOLVAY PHARM GMBH (DE) | 2008-11-19 | — | — | CN | disclosed |
| EP-1960359-A1 | NOVEL N-SULFAMOYL-PIPERIDINEAMIDES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | Solvay Pharmaceuticals GmbH (DE) | 2008-08-27 | — | — | EP | disclosed |
| CN-1997370-A | Medicaments containing N-sulfamoyl-N' -arylpiperazines for the prophylaxis or treatment of obesity and related diseases | SOLVAY PHARM GMBH (DE) | 2007-07-11 | — | — | CN | disclosed |
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH | 2007-06-28 | — | — | US | disclosed |
| WO-2007065948-A1 | NOVEL N-SULFAMOYL-PIPERIDINEAMIDES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
| US-20070117823-A1 | N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof | SOLVAY PHARMACEUTICALSS GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
| EP-1750712-A2 | MEDICAMENTS CONTAINING N-SULFAMOYL-N'-ARYLPIPERAZINES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | Solvay Pharmaceuticals GmbH (DE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005110413-A2 | MEDICAMENTS CONTAINING N-SULFAMOYL-N'-ARYLPIPERAZINES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050261292-A1 | Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | FABP4, GPR119, SRM | HSD17B10 743/4885MEN1 4486/4885KMT2A 793/4885 |
| US-20070117823-A1 | N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof | SCN2A, NAPEPLD, SCN5A | HSD17B10 1309/4885MEN1 469/4885KMT2A 3525/4885 |
| US-20050261292-A1 | Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions | GPR119, FABP4, SULT2A1 | HSD17B10 134/4885MEN1 3510/4885KMT2A 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.